Liberum, a seed-stage venture focused on speeding up enzyme and antibody discovery via its state-of-the-art proprietary cell-free protein synthesis platform, has raised a $1.8 million seed round to increase its production capacity, make additions to its team and expand its suite of available proteins for customers.
Liberum presented at the Early Technology Showcase at the OBIO® Investment Summit.